Codexis Earnings Call Transcripts
Fiscal Year 2026
-
The company is shifting focus from legacy enzyme supply to RNA medicine manufacturing, leveraging its ECO Synthesis platform to address scalability and quality challenges in the growing RNA therapeutics market. Strategic partnerships, new facility investments, and a land-and-expand commercial approach position it for significant growth by 2030.
Fiscal Year 2025
-
2025 marked a pivotal year with strong revenue growth, key commercial agreements, and technical milestones in the ECO Synthesis platform. Guidance for 2026 anticipates continued revenue growth, stable margins, and further expansion in RNA medicine manufacturing.
-
Signed a major Merck agreement, fueling a strategic shift to oligonucleotide manufacturing and Eco-synthesis. Q3 2025 revenue declined year-over-year, but gross margin improved and cash runway now extends through 2027. Leadership transition and new partnerships support growth.
-
Demand for siRNA therapeutics is rapidly increasing, outpacing the capacity of traditional chemical synthesis. Enzymatic manufacturing offers scalable, cost-effective solutions, with recent technical milestones and strong customer engagement driving growth. The company is well-funded and focused on building a robust pipeline and long-term partnerships.
-
Q2 2025 saw revenue nearly double year-over-year, gross margin rise to 72%, and net loss halved. Strong demand for the ECO Synthesis platform is driving capacity expansion, with over 30 customer engagements and new contracts fueling growth.
-
ECO Synthesis platform has rapidly advanced to commercial adoption, with strong industry demand, a growing customer base, and strategic partnerships. Plans include scaling production, onshoring supply chains, and leveraging AI for process optimization, with revenue growth and positive cash flow targeted by end of 2026.
-
siRNA manufacturing is rapidly shifting toward enzymatic synthesis, with the ECO Synthesis platform gaining strong industry validation and customer traction. Technical advances, including machine learning tools and stereochemistry control, are driving adoption, and the platform is on track for full lab capacity and new partnerships.
-
Q1 2025 revenue declined year-over-year due to prior one-time items, but gross margin improved and 2025 guidance is reiterated. ECO Synthesis and RNA ligase businesses are gaining traction, with a strong cash position supporting growth and a projected ramp in the second half of the year.
-
A novel enzymatic platform is addressing the scalability, cost, and environmental challenges of siRNA manufacturing, with tailored commercial strategies and strong regulatory support. AI-driven innovation and expanding market demand for siRNA therapeutics underpin significant growth opportunities.
Fiscal Year 2024
-
Revenue for Q4 2024 was $21.5M, with full-year revenue at $59.3M (excluding Paxlovid). The ECO Synthesis platform is advancing toward commercial contracts in 2025, and double-digit revenue growth is expected. Gross margins are targeted to improve, with cash flow positivity anticipated by end of 2026.
-
The company has strategically pivoted to enzyme-based RNA therapeutics manufacturing, launching the ECO Synthesis platform to address scalability and environmental challenges in siRNA production. With strong commercial traction, advanced scaling partnerships, and disciplined financial management, it targets cash flow positivity by late 2026 and aims to expand into adjacent RNA markets.
-
siRNA therapeutics are rapidly expanding, with enzymatic ECO Synthesis offering a scalable, sustainable alternative to traditional chemical methods. Initial commercial traction with the ligase product is driving near-term revenue, while the full platform is set for a 2026 launch, targeting significant market opportunities and profitability by 2027.
-
Enzymatic synthesis for siRNA is rapidly gaining industry adoption, with Codexis leading in technology and partnerships. The company is scaling up with a new Ecolab, expanding commercial and GMP capabilities, and expects profitability by 2026, supported by strong demand and innovation.
-
The company is advancing its enzyme engineering platform to address the growing siRNA therapeutics market, demonstrating flexible and scalable synthesis methods. Key milestones include scaling production, completing the ECO Innovation Lab, and forming CDMO partnerships, with revenue from the new platform expected by 2027.
-
A complete siRNA drug was synthesized using four methods, showcasing the ecosynthesis platform’s flexibility and performance. Customer interest is high, with new collaborations and the ECO Innovation Lab set to launch. The platform is now seen as a leading, scalable solution for siRNA manufacturing.
-
Q3 2024 revenue grew to $12.8M, driven by pharma manufacturing, with gross margin rising to 61%. Strong cash reserves and targeted investments support a clear path to profitability by 2026, while the ECO Synthesis platform gains traction with major industry players.
-
The company is pivoting to enzymatic RNA production, targeting the growing siRNA market with its ECO Synthesis platform. This approach addresses inefficiencies in current chemical manufacturing, offers scalability, and is gaining validation and commercial traction, with profitability expected by 2026.
-
Q2 2024 revenues met expectations, with $8M total and $6.3M in product revenue, though down year-over-year due to prior non-recurring items. Full-year guidance for at least 10% product revenue growth is reiterated, driven by a strong pharma manufacturing pipeline and new siRNA platform milestones.
-
Significant progress was made in enzymatic siRNA synthesis, with strong customer engagement and the launch of a ligase optimization service. The business is shifting from competition to partnership with major industry players, expects double-digit revenue growth, and aims for positive cash flow by 2026.